P1047: Observational study of tofacitinib in Ulcerative Colitis in Sweden (ODEN) – Interim analysis of health-related quality of life and fatigueECCO'24Year: 2024
Authors: Nyberg, L.(1,2);Söderling, J.(3);Olén, O.(3);Strid, H.(4);Jäghult, S.(5);Halfvarson, J.(6);Hedin, C.(7);Jónsdóttir, S.(8);Hjortswang, H.(9);Cappelleri, J.C.(10);Henrohn, D.(11,12);Seddighzadeh, M.(11);Marsal, J.(1,2);Grip, O.(2)*;
(1)Lund University, Department of Clinical Sciences, Lund, Sweden;(2)Skane University Hospital, Department of Gastroenterology, Lund/Malmö, Sweden;(3)Karolinska Institutet, Clinical Epidemiology, Stockholm, Sweden;(4)Karolinska University Hospital, Department of Gastroenterology, Department of Gastroenterology, Sweden;(5)Karolinska Institutet, Department of Clinical Sciences, Stockholm, Sweden;(6)Örebro University, Institute of Medical Sciences, Örebro, Sweden;(7)Karolinska institutet, Department of Medicine, Stockholm, Sweden;(8)Karolinska university hospital, Department of Gastroenterology, Stockholm, Sweden;(9)University of Linköping, Department of Clinical and Experimental Medicine, Linköping, Sweden;(10)Pfizer Inc, Statistical Research and Data Science Center, Groton- Connecticut, United States;(11)Pfizer AB, Department of Medical Affairs, Stockholm, Sweden;(12)University of Uppsala, Department of Medical Sciences, Uppsala, Sweden;SWIBREG ODEN Study group
P1048: Mirikizumab administration experience from Ulcerative Colitis patients: Survey data from the LUCENT clinical programECCO'24Year: 2024
Authors: Clemow, D.(1)*;Radawski, C.(1);Milata, J.(1);Alaka, K.(1);Hunter Gibble, T.(1);Schaum, A.(1);Ezennia, O.(1);Martinez, N.(2);Szaloki, T.(3);Ito, Y.(4);Rodriguez, D.(5);Kirk, K.(5);
(1)Eli Lilly and Company, Eli Lilly and Company, Indianapolis, United States;(2)Gastroenterology Research of America, Gastroenterology Research of America, San Antonio, United States;(3)Javorszky Hospital, Javorszky Hospital, Vac, Hungary;(4)Mito Medical Center, Mito Medical Center, Ibaraki, Japan;(5)Evidera, Evidera, Bethesda, United States;
P1049: Effectiveness and safety of subcutaneous infliximab in Crohn’s disease patients with immunogenic failure of intravenous infliximabECCO'24Year: 2024
Authors: Husman, J.(1)*;Černá, K.(2);Matthes, K.(1);Gilger, M.(1);Arsova, M.(1);Schmidt, A.(1);Winzer, N.(1);Brosch, A.M.(1);Hampe, J.(1);Zeissig, S.(1);Lukáš, M.(2);Schmelz, R.(1);
(1)University Hospital Carl Gustav Carus Dresden- Technische Universität TU Dresden, Department of Medicine 1, Dresden, Germany;(2)Charles University Prague, Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Prague, Czech Republic;
P104: Per- and poly-fluoroalkyl substances (PFAS) exposure in early life is associated with intestinal inflammationECCO'24Year: 2024
Authors: Agrawal, M.(1,2)*;Midya, V.(3);Picker, M.(4);Rendon, A.(4);Valvi, D.(3);Sabino, J.(5);Dolios, G.(3);Barupal, D.(3);Torres, J.(6,7,8);Petrick, L.(3,9);Colombel, J.F.(1);Peter, I.(4);
(1)Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(2)Aalborg University, Center for Molecular Prediction of Inflammatory Bowel Disease PREDICT- Department of Clinical Medicine, Copenhagen, Denmark;(3)Icahn School of Medicine at Mount Sinai, Department of Environmental Medicine and Public Health, New York, United States;(4)Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences, New York, United States;(5)University Hospital of Leuven, Gastroenterology Division, Leuven, Belgium;(6)The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States;(7)Hospital da Luz, Division of Gastroenterology, Lisbon, Portugal;(8)Hospital Beatriz Ângelo, Division of Gastroenterology, Loures, Portugal;(9)Sheba Medical Center, The Bert Strassburger Metabolic Center, Tel-Hashomer, Israel;
P1050: A cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in FinlandECCO'24Year: 2024
Authors: Metsärinne , K.(1);Säävuori , N.(2)*;Ahmed , W.(3);Pollock-Wilkins , R.(3);Salminen , K.(4);
(1)Turku University Hospital, Department of Medicine, Turku, Finland;(2)Health Data Insights Oy, Health Economics, Janakkala, Finland;(3)Covalence Research Ltd, Health Economics and Outcomes Research, Harpenden, United Kingdom;(4)Turku University Hospital, Department of Gastroenterology, Turku, Finland;
P1051: The role of Resection Margins in Crohn`s Disease – A potential risk factor for Disease Recurrence?ECCO'24Year: 2024
Authors: Kelm, M.(1)*;Buck, V.(2);Benatzky, C.(1);Schöttker, K.(3);Rosenfeldt, M.(2);Germer, C.T.(4);Nusrat, A.(5);Meining, A.(3);Flemming, S.(1);
(1)University Hospital of Würzburg, Department of Surgery, Würzburg, Germany;(2)University of Würzburg, Department of Pathology, Würzburg, Germany;(3)University Hospital of Würzburg, Department of Internal Medicine, Würzburg, Germany;(4)University Hospital of Würzburg, Department of Surgery, Würzburg, Germany;(5)University of Michigan, Department of Pathology, Ann Arbor, United States;
P1052: High doses of methylprednisolone in inducing remission in acute severe ulcerative colitisECCO'24Year: 2024
Authors: Marszk , D.(1);Treder , A.(1); Szlagatys-Sidorkiewicz , A.(2);Brzeziński , M.(2)*;
(1)Copernicus Hospital- Nowe Ogrody 1-6, Department of Pediatrics- Pediatric Gastroenterology- Allergology and Nutrition, Gdańsk, Poland;(2)Medical University of Gdansk, Department of Pediatrics- Gastroenterology- Allergology and Pediatric Nutrition, Gdańsk, Poland;
P1053: Ustekinumab trough concentration could predict the aggravation of endoscopic severity after de-escalation in the sub-analysis of CD-EXTEND study.ECCO'24Year: 2024
Authors: Kato, S.(1)*;Tagawa, K.(1);Yamaga, N.(2);Yakabi, K.(2);Nagoshi, S.(2);
(1)Saitama Medical Centre- Saitama Medical University, Department of Gastroenterology and Hepatology- and Centre for Inflammatory Bowel Disease, Kawagoe City- Saitama, Japan;(2)Saitama Medical Centre- Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe City- Saitama, Japan;
P1054: Clinical outcomes for ulcerative colitis patients stopping 5-aminosalicylates starting biologics and/or immunomodulator therapy: A Systematic review and meta-analysisECCO'24Year: 2024
Authors: Moon, J.R.(1)*;Na , J.E.(2);Ji, J.H.(3);Lee , H.S.(4);Park, J.J.(3);
(1)Inje University Ilsan Paik Hospital, Internal Medicine, Goyang, Korea- Republic Of;(2)Haeundae Paik Hospital- Inje University College of Medicine, Internal Medicine, Busan, Korea- Republic Of;(3)Severance Hospital- Yonsei University College of Medicine, Internal Medicine, Seoul, Korea- Republic Of;(4)Yonsei University College of Medicine, Biostatics Collaboration Unit, Seoul, Korea- Republic Of;
P1055: Intravenous to subcutaneous infliximab switch may reduce the risk of immunogenicity related treatment failure and can be used to facilitate immunomodulator withdrawalECCO'24Year: 2024
Authors: Campbell, I.(1)*;Brownson, E.(1);Bailey, E.(1);Nowell, E.(1);Laird, S.(1);Seenan, J.P.(1);MacDonald, J.(1);
(1)Queen Elizabeth University Hospital, Gastroenterology, Glasgow, United Kingdom;
P1056: T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients with inflammatory bowel disease on TNF inhibitor treatment, a prospective cohort studyECCO'24Year: 2024
Authors: Bjørlykke, K.H.(1); Wolf, A.S.(2); Ørbo, H.S.(3);Bhandari, S.(2);Solum, G.(2);Kjønstad, I.F.(2);Lund , K.P.(4);Tveter, A.T.(5);Sexton, J.(5);Jyssum, I.(5);Kro, G.B.(6); Jahnsen, J.(7);Haavardsholm, E.A.(5);Grødeland, G.(4);Provan, S.A.(5);Kared, H.(4);Lund-Johansen, F.(4);Munthe, L.A.(4);Syversen, S.W.(5);Goll, G.L.(5);Mjaaland, S.(2);Jørgensen, K.K.(1)*;
(1)Akershus University Hospital, Dept. of Gastroenterology, Lørenskog, Norway;(2)Norwegian Institute of Public Health, Div. of Infection Control- Section for Immunology, Oslo, Norway;(3)Diakonhjemmet Hospital, Center for Treatment of Rheumatic and Musculoskeletal Diseases REMEDY Diakonhjemmet Hospital, Oslo, Norway;(4)Oslo University Hospital, Dept. of Immunology, Oslo, Norway;(5)Diakonhjemmet Hospital, Center for Treatment of Rheumatic and Musculoskeletal Diseases REMEDY, Oslo, Norway;(6)Oslo University Hospital, Dept. of Microbiology, Oslo, Norway;(7)Akershus University Hospital, Dept.of Gastroenterology, Lørenskog, Norway;Nor-vaC Study Group
P1057: Upadacitinib as Salvage Therapy for Acute Severe Ulcerative Colitis: A Single-Center ExperienceECCO'24Year: 2024
Authors: St-Pierre, J.(1)*;Choi, D.(1);Krugliak Cleveland, N.(1);Miyatani, Y.(1);Friedberg, S.(1);Choi, N.K.(1);Picker, E.A.(1);Fear, E.(1);Fine, Z.(1);Han, J.(1);Labas, J.(1);Rubin, D.T.(1);
(1)University of Chicago, Inflammatory Bowel Disease Center, Chicago, United States;
P1058: Safety and effectiveness of subcutaneous infliximab formulation in difficult-to-treat Crohn’s Disease patients with previous exposure to intravenous infliximab: A case-series.ECCO'24Year: 2024
Authors: Mulinacci, G.(1)*;Pirola, L.(1);Piazza O Sed, N.(2);Laffusa, A.(1);Fichera, M.(1);Massironi, S.(1);Invernizzi, P.(1);Caprioli, F.A.(3);Viganò, C.(1);
(1)European Reference Network on Hepatological Diseases ERN RARE-LIVER- Fondazione IRCCS San Gerardo dei Tintori- Monza- Italia, Division of Gastroenterology- Center for Autoimmune Liver Diseases- Department of Medicine and Surgery- University of Milano-Bicocca, Monza, Italy;(2)Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan- Italy, Gastroenterology and Endoscopy Unit, Milano, Italy;(3)Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan- Italy, Gastroenterology and Endoscopy Unit- Department of Pathophysiology and Transplantation- University of Milan, Milano, Italy;
P1059: Use of preoperative transjugular intrahepatic portosystemic shunt (TIPS) in patients with Inflammatory Bowel Disease and cirrhosisECCO'24Year: 2024
Authors: Karime, C.(1)*;Vattikonda, A.(1);Hashash, J.G.(2);Merchea, A.(3);Stocchi, L.(3);Farraye, F.A.(2);
(1)Mayo Clinic, Department of Internal Medicine, Jacksonville, United States;(2)Mayo Clinic, Inflammatory Bowel Disease Center- Department of Gastroenterology, Jacksonville, United States;(3)Mayo Clinic, Department of Colon and Rectal Surgery, Jacksonville, United States;
P1061: TEV-48574, an anti-TL1A antibody in development for use in IBD, is safe and well tolerated following 16 weeks of subcutaneous treatment in adults with severe uncontrolled T2-low/non T2 asthmaECCO'24Year: 2024
Authors: Raphael, G.(1)*;Damera, G.(1);Angeles, T.(1);Li, S.(1);Stoyanov, S.(1);
(1)Teva Branded Pharmaceutical Products, Research and Development, West Chester PA, United States;
P1062: Effectiveness and safety outcomes beyond five years of IBD patients treated with vedolizumab. The LONG-LIVE IG-IBD study.ECCO'24Year: 2024
Authors: Privitera, G.(1)*;Pugliese, D.(2);Armuzzi, A.(3);
(1)Dipartimento Scienze della Salute, Università degli Studi di Milano, Milano, Italy;(2)Fondazione Policlinico Universitario Agostino Gemelli- IRCCS, Dipartimento di Medicina e Chirurgia Traslazionale, Rome, Italy;(3)Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Italy;LIVE IG-IBD Study Group
P1063: Comparison of all paediatric patients and young adults with Crohn’s Disease treated with ustekinumab in the REALITI Real-World Evidence Effectiveness StudyECCO'24Year: 2024
Authors: Shehzad, S.(1)*;Steiner, S.(2);Adler, J.(3);Colletti, R.B.(4);Strauss, R.(5);Heile, J.(6);Adedokun, O.(7);Sheahan, A.(8);Zhang, R.(9);Lo, K.H.(10);Kim, L.(10);Xiao, Y.(11);Volger, S.(5);
(1)Dayton Children@E@s Hospital/Wright State University, Clinically Integrated Network, Dayton, United States;(2)Riley Hospital for Children- Indiana University School of Medicine, Pediatric Gastroenterology- Hepatology and Nutrition, Indianapolis, United States;(3)University of Michigan, Pediatric Gastroenterology Clinic, Ann Arbor, United States;(4)University of Vermont Children@E@s Hospital, Pediatrics, Burlington, United States;(5)Janssen Research & Development- LLC, Pediatric Development Team, Spring House, United States;(6)Cilag GmbH International, Global Regulatory Affairs, Zug, United States;(7)Janssen Research & Development- LLC, Global Clinical Pharmacology & Pharmacometrics, Spring House, United States;(8)Janssen Research & Development- LLC, Immunology Epidemiology, Titusville, United States;(9)Janssen Research & Development- LLC, CA Data Analysis, San Diego, United States;(10)Janssen Research & Development- LLC, Statistics and Decision Sciences, Spring House, United States;(11)Cytel, Statistics, Waltham, United States;
P1064: Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to TofacitinibECCO'24Year: 2024
Authors: Gilmore, R.(1,2)*;Fernandes, R.(1,2);Hartley, I.(3);Arzivian, A.(4);Leong, R.(4);Andrew, B.(5);Vasudevan, A.(5);Greeve, T.(6);Moore, G.(6);Kim, S.(7);Lightowler, D.(8);Singh, A.(7);Mahy, G.(9);Mithanthaya, A.(10);Venugpal, K.(10);Han, S.(11);Bryant, R.(11);West, J.(12);Segal, J.(12);Christensen, B.(12);Ding, N.J.(3);An, Y.K.(1,2);Begun, J.(1,2);
(1)Mater Hospital, Department of Gastroenterology, Brisbane, Australia;(2)Mater Research Institute, University of Queensland, Brisbane, Australia;(3)St Vincent@E@s Hospital, Department of Gastroenterology, Melbourne, Australia;(4)Macquarie University Hospital, Department of Gastroenterology, Sydney, Australia;(5)Eastern Health, Department of Gastroenterology, Melbourne, Australia;(6)Monash Health, Department of Gastroenterology, Melbourne, Australia;(7)Fiona Stanley Hospital, Department of Gastroenterology, Perth, Australia;(8)Wexford Gastroenterology, Department of Gastroenterology, Perth, Australia;(9)Townsville University Hospital, Department of Gastroenterology, Townsville, Australia;(10)Royal Perth Hospital, Department of Gastroenterology, Perth, Australia;(11)The Queen Elizabeth Hospital, Department of Gastroenterology, Adelaide, Australia;(12)Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia;
